Telerehabilitation for patients with fibrosing interstitial lung disease
Telerehabilitation in Patients With Fibrosing Interstitial Lung Diseases
This study is testing different exercise programs to see which one helps people with fibrosing interstitial lung disease feel better, including online sessions with a physiotherapist, video workouts, and traditional hospital rehab.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 63 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Saglik Bilimleri Universitesi Academic / other |
| Locations | 1 site (İstanbul, Üsküdar) |
| Trial ID | NCT05166057 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the effectiveness of various exercise programs for patients with fibrosing interstitial lung disease (FILD) by randomly assigning participants into three groups: a telerehabilitation exercise group, a video-based exercise group, and a standard pulmonary rehabilitation group. The telerehabilitation group will engage in online exercises with a physiotherapist, while the video group will follow pre-recorded exercise videos. The standard group will participate in supervised hospital-based rehabilitation. Each program lasts for 8 weeks and includes aerobic, resistance, and breathing exercises.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18-75 diagnosed with fibrosing interstitial lung disease who can use a smartphone and experience dyspnea on exertion.
Not a fit: Patients with severe comorbidities, unstable coronary artery disease, or those requiring high flow oxygen therapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance rehabilitation options for patients with fibrosing interstitial lung disease, potentially improving their physical function and quality of life.
How similar studies have performed: Other studies have shown promising results with telerehabilitation approaches for various conditions, suggesting potential success for this novel application in fibrosing interstitial lung disease.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Being between the ages of 18-75 * Have a diagnosis of fibrosing interstitial lung disease diagnosed according to the clinical diagnostic criteria of the American Thoracic and European Respiratory Societies (ATS-ERS). * Presence of dyspnea on exertion Stable clinical state at the time of admission without infection or exacerbation in the previous 4 weeks * Ability to use a smart phone Exclusion Criteria: * Patients with severe comorbid diseases, unstable coronary artery disease, collagen vascular diseases and needing high flow oxygen therapy (˃ 3-4 L \\min). * history of effort-related syncope or any comorbidity (such as severe orthopedic or neurological deficits or unstable heart disease) that precludes exercise training. * Participating in a pulmonary rehabilitation program within the past 12 months.
Where this trial is running
İstanbul, Üsküdar
- Esra Pehlivan — İstanbul, Üsküdar, Turkey (Recruiting)
Study contacts
- Study coordinator: ESRA PEHLİVAN, Assoc.Prof.
- Email: fztesrakambur@yahoo.com
- Phone: 02164189616
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.